Thymoquinone / IL1β Cancer Research Results

TQ, Thymoquinone: Click to Expand ⟱
Features: Anti-oxidant, anti-tumor
Thymoquinone is a bioactive compound found in the seeds of Nigella sativa, commonly known as black seed or black cumin.
Pathways:
-Cell cycle arrest, apoptosis induction, ROS generation in cancer cells
-inhibit the activation of NF-κB, Suppress the PI3K/Akt signaling cascade
-Inhibit angiogenic factors such as VEGF, MMPs
-Inhibit HDACs, UHRF1, and DNMTs

-Note half-life 3-6hrs.
BioAv low oral bioavailability due to its lipophilic nature. Note refridgeration of Black seed oil improves the stability of TQ.
DIY: ~1 part lecithin : 2–3 parts black seed oil : 4–5 parts warm water. (chat ai)
Pathways:
- usually induce ROS production in Cancer cells, and lowers ROS in normal cells
- ROS↑ related: MMP↓(ΔΨm), ER Stress↑, GRP78↑, Cyt‑c↑, Caspases↑, DNA damage↑, cl-PARP↑, HSP↓, Prx,
- May Low AntiOxidant defense in Cancer Cells: NRF2↓(usually contrary), GSH↓ HO1↓(contrary), GPx↓
- Raises AntiOxidant defense in Normal Cells: ROS↓, NRF2↑, SOD↑, GSH↑, Catalase↑,
- lowers Inflammation : NF-kB↓, COX2↓, p38↓, Pro-Inflammatory Cytokines : NLRP3↓, IL1β↓">IL-1β↓, TNF-α↓, IL-6↓, IL-8↓
- inhibit Growth/Metastases : TumMeta↓, TumCG↓, EMT↓, MMPs↓, MMP2↓, MMP9↓, VEGF↓, FAK↓, NF-κB↓, CXCR4↓, TGF-β↓, ERK↓
- reactivate genes thereby inhibiting cancer cell growth : HDAC↓, DNMTs↓, EZH2↓, P53↑, HSP↓, Sp proteins↓, TET↑
- cause Cell cycle arrest : TumCCA↑, cyclin D1↓, cyclin E↓, CDK2↓, CDK4↓, CDK6↓,
- inhibits Migration/Invasion : TumCMig↓, TumCI↓, TNF-α↓, FAK↓, ERK↓, EMT↓,
- inhibits glycolysis /Warburg Effect and ATP depletion : HIF-1α↓, PKM2↓, cMyc↓, GLUT1↓, LDH↓, LDHA↓, HK2↓, PDKs↓, GRP78↑, GlucoseCon↓
- inhibits angiogenesis↓ : VEGF↓, HIF-1α↓, Notch↓, EGFR↓, Integrins↓,
- Others: PI3K↓, AKT↓, JAK↓, STAT↓, Wnt↓, β-catenin↓, AMPK, α↓, ERK↓, JNK,
- Synergies: chemo-sensitization, chemoProtective, RadioSensitizer, RadioProtective, Others(review target notes), Neuroprotective, Cognitive, Renoprotection, Hepatoprotective, CardioProtective,

- Selectivity: Cancer Cells vs Normal Cells

Rank Pathway / Target Axis Direction Label Primary Effect Notes / Cancer Relevance Ref
1 Reactive oxygen species (ROS) ↑ ROS Driver Upstream cytotoxic trigger Primary studies show TQ rapidly increases ROS; antioxidant/ROS modulation attenuates downstream effects, supporting ROS as an initiating mechanism in multiple cancer contexts (ref)
2 Glutathione (GSH) redox buffering ↓ GSH Driver Redox-collapse amplification Same prostate cancer study reports early GSH depletion alongside ROS rise; together these form a redox “one-two punch” that helps explain selective stress in tumor cells (ref)
3 Mitochondrial integrity (ΔΨm) ↓ ΔΨm Driver Mitochondrial dysfunction (MOMP axis) Primary leukemia/cancer study reports disruption of mitochondrial membrane potential after TQ exposure (mitochondrial events central to TQ-mediated death) (ref)
4 Intrinsic apoptosis (caspase-9 → caspase-3; PARP) ↑ caspases / ↑ apoptosis Driver Execution-phase cell death Same primary paper reports activation of caspases (8/9/3) with mitochondrial involvement—core evidence for apoptosis as the major outcome pathway (ref)
5 NF-κB signaling ↓ NF-κB activity Secondary Reduced pro-survival / inflammatory transcription Colon cancer work: TQ induces cell death and chemosensitizes cells by inhibiting NF-κB signaling (explicit pathway-direction support) (ref)
6 STAT3 signaling ↓ p-STAT3 / ↓ STAT3 activation Secondary Reduced survival/proliferation signaling Gastric cancer study explicitly reports TQ suppresses constitutive STAT3 activation and related signaling readouts (ref)
7 NRF2 antioxidant-response axis (NRF2/HO-1 program) ↑ NRF2 pathway (often as stress-response) Adaptive Cellular antioxidant counter-response In TNBC context, a primary study reports TQ upregulates NRF2 (and evaluates downstream immune/checkpoint consequences), consistent with NRF2 acting as an adaptive response to redox stress (ref)
8 HIF-1α hypoxia signaling ↓ HIF-1α protein / ↓ HIF-1α program Adaptive Loss of hypoxia survival signaling Renal cancer hypoxia paper identifies TQ as suppressing HIF-1α and links this to selective killing under hypoxia (ref)
9 Glycolysis / Warburg output (hypoxia-linked) ↓ glycolysis (↓ HIF-1α–mediated glycolytic genes; ↓ glycolytic metabolism) Phenotypic Metabolic suppression In hypoxic renal cancer, TQ suppresses HIF-1α–mediated glycolysis; in CRC, TQ inhibits glycolytic metabolism alongside tumor growth limitation (ref)  |  (ref)


IL1β, interleukin-1 beta: Click to Expand ⟱
Source:
Type:
The term "IL-1" is often used as an umbrella term for the interleukin-1 family, which includes multiple cytokines. The two best-known members are IL-1α and IL-1β.
IL-1β is secreted from cells and plays a major systemic role in inflammation. It is a crucial mediator in the inflammatory response and is involved in the fever response, activation of endothelial cells, and leukocyte recruitment.
Its increased expression is commonly linked to:
  – Promotion of a pro-inflammatory microenvironment that supports tumor growth.
  – Enhanced angiogenesis, invasion, and metastasis.
  – Recruitment of myeloid cells that may further suppress antitumor immunity.

High expression of either tends to be associated with a more aggressive phenotype and worse prognosis in many cancer types.
Scientific Papers found: Click to Expand⟱
2207- AgNPs,  TQ,    Protective effects of Nigella sativa L. seeds aqueous extract-based silver nanoparticles on sepsis-induced damages in rats
- in-vivo, Nor, NA
*eff↑, *RenoP↑, *hepatoP↑, *MDA↓, *SOD↑, *GSH↑, *TNF-α↓, *IL1β↓,
3407- TQ,    Thymoquinone and its pharmacological perspective: A review
- Review, NA, NA
*antiOx↑, *ROS↓, *GSTs↑, *GSR↑, *GSH↑, *RenoP↑, *IL1β↓, *TNF-α↓, *MMP13↓, *COX2↓, *PGE2↓, *radioP↑, Twist↓, EMT↓, NF-kB↓, p‑PI3K↓, p‑Akt↓, p‑GSK‐3β↓, DNMT1↓, HDAC↓,
3409- TQ,    Thymoquinone therapy remediates elevated brain tissue inflammatory mediators induced by chronic administration of food preservatives
- in-vivo, Nor, NA
*MDA↓, *TGF-β↓, *CRP↓, *NF-kB↓, *TNF-α↓, *IL1β↓, *Casp3↓, *GSH↑, *NRF2↑, *IL10↑, *neuroP↑, *ROS↓, *Apoptosis↓, *Inflam↓,
3410- TQ,    Anti-inflammatory effects of thymoquinone and its protective effects against several diseases
- Review, Arthritis, NA
*Inflam↓, *antiOx↑, *COX2↓, *NRF2↑, *HO-1↑, *IL1β↓, *IL6↓, *TNF-α↓, *IFN-γ↓, *PGE2↓, *cardioP↑, *Catalase↑, *SOD↑, *Thiols↑, *neuroP↑, *IL12↓, *MCP1↓, *CXCc↓, *ROS↓,
3404- TQ,    The Neuroprotective Effects of Thymoquinone: A Review
- Review, Var, NA - Review, AD, NA - Review, Park, NA - Review, Stroke, NA
*Inflam↓, AntiCan↑, *TNF-α↓, *IL6↓, *IL1β↓, *NF-kB↓, *iNOS↓, *NRF2↑, *neuroP↑, *MMP↑, *ROS↓, *MDA↓, *GSH↑, *Catalase↑, *SOD↑, *IL12↓, *MCP1↓, *IP-10/CXCL-10↓, *PGE2↓,
3418- TQ,    Thymoquinone suppresses metastasis of melanoma cells by inhibition of NLRP3 inflammasome
- in-vitro, Melanoma, A375 - in-vivo, NA, NA
TumMeta↓, TumCMig↓, NLRP3↓, Casp1↓, IL1β↓, IL18↓, ROS↓, NF-kB↓,
3419- TQ,    Thymoquinone, a Novel Multi-Strike Inhibitor of Pro-Tumorigenic Breast Cancer (BC) Markers: CALR, NLRP3 Pathway and sPD-L1 in PBMCs of HR+ and TNBC Patients
- in-vitro, BC, NA
*NLRP3↓, *IL1β↓, *Casp1?,
3420- TQ,    Thymoquinone alleviates the accumulation of ROS and pyroptosis and promotes perforator skin flap survival through SIRT1/NF-κB pathway
- in-vitro, Nor, HUVECs - in-vitro, NA, NA
*NF-kB↓, *NLRP3↓, *angioG↑, *MMP9↑, *VEGF↑, *OS↑, *Pyro?, *ROS↓, *Apoptosis↓, *SIRT1↑, *SOD1↑, *HO-1↑, *eNOS↑, *ASC?, *Casp1↓, *IL1β↓, *IL18↓,
3422- TQ,    Thymoquinone, as a Novel Therapeutic Candidate of Cancers
- Review, Var, NA
selectivity↑, P53↑, PTEN↑, NF-kB↓, PPARγ↓, cMyc↓, Casp↑, *BioAv↓, BioAv↝, eff↑, survivin↓, Bcl-xL↓, Bcl-2↓, Akt↓, BAX↑, cl‑PARP↑, CXCR4↓, MMP9↓, VEGFR2↓, Ki-67↓, COX2↓, JAK2↓, cSrc↓, Apoptosis↑, p‑STAT3↓, cycD1/CCND1↓, Casp3↑, Casp7↑, Casp9↑, N-cadherin↓, Vim↓, Twist↓, E-cadherin↑, ChemoSen↑, eff↑, EMT↓, ROS↑, DNMT1↓, eff↑, EZH2↓, hepatoP↑, Zeb1↓, RadioS↑, HDAC↓, HDAC1↓, HDAC2↓, HDAC3↓, *NAD↑, *SIRT1↑, SIRT1↓, *Inflam↓, *CRP↓, *TNF-α↓, *IL6↓, *IL1β↓, *eff↑, *MDA↓, *NO↓, *GSH↑, *SOD↑, *Catalase↑, *GPx↑, PI3K↓, mTOR↓,
3400- TQ,  Chemo,    Thymoquinone Ameliorates Carfilzomib-Induced Renal Impairment by Modulating Oxidative Stress Markers, Inflammatory/Apoptotic Mediators, and Augmenting Nrf2 in Rats
- in-vitro, Nor, NA
*GSH↑, *SOD↑, *lipid-P↓, *IL1β↓, *IL6↓, *TNF-α↓, *Casp3↓, *Catalase↑, *NRF2↑, *RenoP↑,
3398- TQ,  5-FU,    Impact of thymoquinone on the Nrf2/HO-1 and MAPK/NF-κB axis in mitigating 5-fluorouracil-induced acute kidney injury in vivo
- in-vivo, Nor, NA
*RenoP↑, *TAC↑, *ROS↓, *lipid-P↓, *p38↓, *MAPK↓, *NF-kB↓, *NRF2↑, *HO-1↑, *MDA↓, *GPx↑, *GSR↑, *Catalase↑, *BUN↓, *LDH↓, *IL1β↓,
3397- TQ,    Thymoquinone: A Promising Therapeutic Agent for the Treatment of Colorectal Cancer
- Review, CRC, NA
ChemoSen↑, *Half-Life↝, *BioAv↝, *antiOx↑, *Inflam↓, *hepatoP↑, TumCP↓, TumCCA↑, Apoptosis↑, angioG↑, selectivity↑, JNK↑, p38↑, p‑NF-kB↑, ERK↓, PI3K↓, PTEN↑, Akt↓, mTOR↓, EMT↓, Twist↓, E-cadherin↓, ROS⇅, *Catalase↑, *SOD↑, *GSTA1↑, *GPx↑, *PGE2↓, *IL1β↓, *COX2↓, *MMP13↓, MMPs↓, TumMeta↓, VEGF↓, STAT3↓, BAX↑, Bcl-2↑, Casp9↑, Casp7↑, Casp3↑, cl‑PARP↑, survivin↓, cMyc↓, cycD1/CCND1↓, p27↑, P21↑, GSK‐3β↓, β-catenin/ZEB1↓, chemoP↑,
3570- TQ,    Thymoquinone alleviates the experimentally induced Alzheimer's disease inflammation by modulation of TLRs signaling
- in-vivo, AD, NA
*Inflam↓, *Aβ↓, *TNF-α↓, *IL1β↓, *TLR2↓, *IRF3↓, *TLR4↓, *memory↑, *NF-kB↓, *MyD88↓, *TRIF↓, *BBB↑, *cognitive↑,
3571- TQ,    The Role of Thymoquinone in Inflammatory Response in Chronic Diseases
- Review, Var, NA - Review, Stroke, NA
*BioAv↓, *BioAv↑, *Inflam↓, *antiOx↑, *ROS↓, *GSH↑, *GSTs↑, *MPO↓, *NF-kB↓, *COX2↓, *IL1β↓, *TNF-α↓, *IFN-γ↓, *IL6↓, *cardioP↑, *lipid-P↓, *TAC↑, *RenoP↑, Apoptosis↑, TumCCA↑, TumCP↓, TumCMig↓, angioG↓, TNF-α↓, NF-kB↓, ROS↑, EMT↓, *Aβ↓, *p‑tau↓, *BACE↓, *TLR2↓, *TLR4↓, *MyD88↓, *IRF3↓, *eff↑, eff↑, DNAdam↑, *iNOS↓,
3559- TQ,    Molecular signaling pathway targeted therapeutic potential of thymoquinone in Alzheimer’s disease
- Review, AD, NA - Review, Var, NA
*antiOx↑, *Inflam↓, *AChE↓, AntiCan↑, *cardioP↑, *RenoP↑, *neuroP↑, *hepatoP↑, TumCG↓, Apoptosis↑, PI3K↓, Akt↑, TumCCA↑, angioG↓, *NF-kB↓, *TLR2↓, *TLR4↓, *MyD88↓, *TRIF↓, *IRF3↓, *IL1β↓, *IL6↓, *IL12↓, *NRF2↑, *COX2↓, *VEGF↓, *MMP9↓, *cMyc↓, *cycD1/CCND1↓, *TumCP↓, *TumCI↓, *MDA↓, *TGF-β↓, *CRP↓, *Casp3↓, *GSH↑, *IL10↑, *iNOS↑, *lipid-P↓, *SOD↑, *H2O2↓, *ROS↓, *LDH↓, *Catalase↑, *GPx↑, *AChE↓, *cognitive↑, *MAPK↑, *JNK↑, *BAX↓, *memory↑, *Aβ↓, *MMP↑,
3557- TQ,    Thymoquinone protects against lipopolysaccharides-induced neurodegeneration and Alzheimer-like model in mice.
- in-vivo, AD, NA
*Inflam↓, *antiOx↑, *cognitive↑, *TNF-α↓, *IL1β↓, *AChE↓, *IL10↑, *ChAT↑, *Aβ↓,
3556- TQ,    Thymoquinone alleviates the experimentally induced Alzheimer’s disease inflammation by modulation of TLRs signaling
- in-vivo, AD, NA
*Inflam↓, *memory↑, *cognitive↑, *Aβ↓, *TNF-α↓, *IL1β↓, *TLR2↓, *NF-kB↓, *IRF3↓, TLR4↓, MyD88↓, TRIF↓,
2103- TQ,    Anti-inflammatory effects of the Nigella sativa seed extract, thymoquinone, in pancreatic cancer cells
- in-vitro, PC, Hs766t - in-vitro, PC, MIA PaCa-2
MCP1↓, TNF-α↓, IL1β↓, COX2↓, NF-kB↓, HDAC↓, P21↑,

Showing Research Papers: 1 to 18 of 18

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 18

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

ROS↓, 1,   ROS↑, 2,   ROS⇅, 1,  

Core Metabolism/Glycolysis ⓘ

cMyc↓, 2,   PPARγ↓, 1,   SIRT1↓, 1,  

Cell Death ⓘ

Akt↓, 2,   Akt↑, 1,   p‑Akt↓, 1,   Apoptosis↑, 4,   BAX↑, 2,   Bcl-2↓, 1,   Bcl-2↑, 1,   Bcl-xL↓, 1,   Casp↑, 1,   Casp1↓, 1,   Casp3↑, 2,   Casp7↑, 2,   Casp9↑, 2,   JNK↑, 1,   p27↑, 1,   p38↑, 1,   survivin↓, 2,  

Kinase & Signal Transduction ⓘ

cSrc↓, 1,  

Transcription & Epigenetics ⓘ

EZH2↓, 1,  

DNA Damage & Repair ⓘ

DNAdam↑, 1,   DNMT1↓, 2,   P53↑, 1,   cl‑PARP↑, 2,  

Cell Cycle & Senescence ⓘ

cycD1/CCND1↓, 2,   P21↑, 2,   TumCCA↑, 3,  

Proliferation, Differentiation & Cell State ⓘ

EMT↓, 4,   ERK↓, 1,   GSK‐3β↓, 1,   p‑GSK‐3β↓, 1,   HDAC↓, 3,   HDAC1↓, 1,   HDAC2↓, 1,   HDAC3↓, 1,   mTOR↓, 2,   PI3K↓, 3,   p‑PI3K↓, 1,   PTEN↑, 2,   STAT3↓, 1,   p‑STAT3↓, 1,   TumCG↓, 1,  

Migration ⓘ

E-cadherin↓, 1,   E-cadherin↑, 1,   Ki-67↓, 1,   MMP9↓, 1,   MMPs↓, 1,   N-cadherin↓, 1,   TumCMig↓, 2,   TumCP↓, 2,   TumMeta↓, 2,   Twist↓, 3,   Vim↓, 1,   Zeb1↓, 1,   β-catenin/ZEB1↓, 1,  

Angiogenesis & Vasculature ⓘ

angioG↓, 2,   angioG↑, 1,   VEGF↓, 1,   VEGFR2↓, 1,  

Immune & Inflammatory Signaling ⓘ

COX2↓, 2,   CXCR4↓, 1,   IL18↓, 1,   IL1β↓, 2,   JAK2↓, 1,   MCP1↓, 1,   MyD88↓, 1,   NF-kB↓, 5,   p‑NF-kB↑, 1,   TLR4↓, 1,   TNF-α↓, 2,   TRIF↓, 1,  

Protein Aggregation ⓘ

NLRP3↓, 1,  

Drug Metabolism & Resistance ⓘ

BioAv↝, 1,   ChemoSen↑, 2,   eff↑, 4,   RadioS↑, 1,   selectivity↑, 2,  

Clinical Biomarkers ⓘ

EZH2↓, 1,   Ki-67↓, 1,  

Functional Outcomes ⓘ

AntiCan↑, 2,   chemoP↑, 1,   hepatoP↑, 1,  
Total Targets: 87

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress ⓘ

antiOx↑, 6,   Catalase↑, 7,   GPx↑, 4,   GSH↑, 8,   GSR↑, 2,   GSTA1↑, 1,   GSTs↑, 2,   H2O2↓, 1,   HO-1↑, 3,   lipid-P↓, 4,   MDA↓, 6,   MPO↓, 1,   NRF2↑, 6,   ROS↓, 8,   SOD↑, 7,   SOD1↑, 1,   TAC↑, 2,   Thiols↑, 1,  

Mitochondria & Bioenergetics ⓘ

MMP↑, 2,  

Core Metabolism/Glycolysis ⓘ

BUN↓, 1,   cMyc↓, 1,   LDH↓, 2,   NAD↑, 1,   SIRT1↑, 2,  

Cell Death ⓘ

Apoptosis↓, 2,   BAX↓, 1,   Casp1?, 1,   Casp1↓, 1,   Casp3↓, 3,   iNOS↓, 2,   iNOS↑, 1,   JNK↑, 1,   MAPK↓, 1,   MAPK↑, 1,   p38↓, 1,   Pyro?, 1,  

Cell Cycle & Senescence ⓘ

cycD1/CCND1↓, 1,  

Migration ⓘ

MMP13↓, 2,   MMP9↓, 1,   MMP9↑, 1,   TGF-β↓, 2,   TumCI↓, 1,   TumCP↓, 1,  

Angiogenesis & Vasculature ⓘ

angioG↑, 1,   eNOS↑, 1,   NO↓, 1,   VEGF↓, 1,   VEGF↑, 1,  

Barriers & Transport ⓘ

BBB↑, 1,  

Immune & Inflammatory Signaling ⓘ

ASC?, 1,   COX2↓, 5,   CRP↓, 3,   CXCc↓, 1,   IFN-γ↓, 2,   IL10↑, 3,   IL12↓, 3,   IL18↓, 1,   IL1β↓, 16,   IL6↓, 6,   Inflam↓, 10,   IP-10/CXCL-10↓, 1,   MCP1↓, 2,   MyD88↓, 3,   NF-kB↓, 8,   PGE2↓, 4,   TLR2↓, 4,   TLR4↓, 3,   TNF-α↓, 11,   TRIF↓, 2,  

Synaptic & Neurotransmission ⓘ

AChE↓, 3,   ChAT↑, 1,   p‑tau↓, 1,  

Protein Aggregation ⓘ

Aβ↓, 5,   BACE↓, 1,   NLRP3↓, 2,  

Drug Metabolism & Resistance ⓘ

BioAv↓, 2,   BioAv↑, 1,   BioAv↝, 1,   eff↑, 3,   Half-Life↝, 1,  

Clinical Biomarkers ⓘ

CRP↓, 3,   IL6↓, 6,   LDH↓, 2,  

Functional Outcomes ⓘ

cardioP↑, 3,   cognitive↑, 4,   hepatoP↑, 3,   memory↑, 3,   neuroP↑, 4,   OS↑, 1,   radioP↑, 1,   RenoP↑, 6,  

Infection & Microbiome ⓘ

IRF3↓, 4,  
Total Targets: 92

Scientific Paper Hit Count for: IL1β, interleukin-1 beta
18 Thymoquinone
1 Silver-NanoParticles
1 Chemotherapy
1 5-fluorouracil
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:162  Target#:978  State#:%  Dir#:1
  wNotes=0  sortOrder:rid,rpid

 

Home Page